Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 8/20 | 0.36 |
| ▸ | CA2 | P00918 | 8/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | CA9 | Q16790 | 6/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642848 | 1.00 | COMT (0.66) | COMTCA1CA2CA12CA9 | |
| SCHEMBL29642781 | 0.91 | COMT (0.58) | COMTCA1CA2CA12CA9 | |
| SCHEMBL20590973 | 0.91 | COMT (0.58) | COMTCA1CA2CA12CA9 | |
| SCHEMBL18986811 | 0.88 | COMT (0.72) | COMT | |
| SCHEMBL31514946 | 0.87 | COMT (0.47) | COMTCA1CA2CA12CA9 | |
| SCHEMBL31514934 | 0.87 | COMT (0.47) | COMTCA1CA2CA12CA9 | |
| SCHEMBL29642891 | 0.83 | COMT (0.79) | COMTMAOAMAOB | |
| SCHEMBL18987105 | 0.83 | COMT (0.79) | COMTMAOAMAOB | |
| SCHEMBL18987117 | 0.81 | COMT (1.00) | COMT | |
| SCHEMBL31514945 | 0.81 | COMT (1.00) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390351-B1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | KOESTER HUBERT (DE) | 2025-02-26 | — | — | EP | claimed |
| US-11008282-B2 | Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | KOESTER HUBERT (CH) | 2021-05-18 | — | — | US | claimed |
| US-20180370906-A1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | Koester, Hubert (CH) | 2018-12-27 | — | — | US | claimed |
| EP-3390351-B1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | KOESTER HUBERT (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-108698984-B | Bicyclic compounds for use as medicaments, in particular for the treatment of parkinson's disease | H·科斯特 | 2022-05-10 | — | — | CN | disclosed |
| WO-2017103278-A1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370906-A1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | COMT, DBH, PNMT | COMT 1/4885CA1 4032/4885CA2 2100/4885 |
| US-11008282-B2 | Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | COMT, PNMT, DBH | COMT 1/4885CA1 3762/4885CA2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.